We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

28 hedge funds and large institutions have $803K invested in Aevi Genomic Medicine Inc in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

26% less funds holding

Funds holding: 38 → 28 (-10)

91% less capital invested

Capital invested by funds: $8.64M → $803K (-$7.83M)

91% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 11

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
28
Holders Change
-10
Holders Change %
-26.32%
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
7
Reduced
5
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$228K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$55.1K
3
VF
Virtu Financial
New York
+$53.9K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$20.9K
5
UBS Group
UBS Group
Switzerland
+$16K

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.85M
2
BBA
Baker Bros. Advisors
New York
-$2.77M
3
WS
Wedbush Securities
California
-$141K
4
Millennium Management
Millennium Management
New York
-$43K
5
AMCA
Arthur M. Cohen & Associates
Illinois
-$38.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$214K +$228K +1,027,040 +1,583%
BlackRock
2
BlackRock
New York
$153K -$1.18K -5,297 -0.7%
Vanguard Group
3
Vanguard Group
Pennsylvania
$134K -$8.93K -40,240 -6%
VF
4
Virtu Financial
New York
$55K +$53.9K +242,994 +676%
Acadian Asset Management
5
Acadian Asset Management
Massachusetts
$53K +$55.1K +248,476 +1,279%
BCM
6
Bridgeway Capital Management
Texas
$44K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$32K – – –
BC
8
Birchview Capital
Vermont
$25K – – –
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$25K +$20.9K +94,268 +285%
UBS Group
10
UBS Group
Switzerland
$15K +$16K +72,032 +1,441%
Citadel Advisors
11
Citadel Advisors
Florida
$13K +$11.2K +50,537 +320%
California Public Employees Retirement System
12
California Public Employees Retirement System
California
$10K – – –
Northern Trust
13
Northern Trust
Illinois
$10K – – –
Bank of New York Mellon
14
Bank of New York Mellon
New York
$5K -$177 -798 -3%
Wells Fargo
15
Wells Fargo
California
$3K -$25.4K -114,678 -88%
OIA
16
OneDigital Investment Advisors
Kansas
$3K – – –
State Street
17
State Street
Massachusetts
$3K – – –
VAM
18
Verity Asset Management
North Carolina
$3K – – –
MWP
19
MYCIO Wealth Partners
Pennsylvania
$2K – – –
LTFS
20
Ladenburg Thalmann Financial Services
Florida
$1K +$1.11K +5,000 +313%
Adage Capital Partners
21
Adage Capital Partners
Massachusetts
– -$3.85M -5,500,000 Closed
BBA
22
Baker Bros. Advisors
New York
– -$2.77M -3,950,419 Closed
WS
23
Wedbush Securities
California
– -$141K -201,774 Closed
Millennium Management
24
Millennium Management
New York
– -$43K -61,223 Closed
AMCA
25
Arthur M. Cohen & Associates
Illinois
– -$38.6K -31,390 Closed
1
2

GNMX Hedge Fund Activity: Q1 2019 in Review

28 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q1 2019, worth a combined $803K — down 91% from $8.64M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of GNMX and 1 opened new positions — a net loss of 10 holders — while 5 trimmed existing stakes and 7 added.

The largest buyer was Renaissance Technologies, adding an estimated $228K. The largest seller was Adage Capital Partners, exiting entirely with an estimated $3.85M sold.

  • 28 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q1 2019, down from 38 in Q4 2018.
  • Funds reported $803K of Aevi Genomic Medicine Inc stock for Q1 2019, down 91% quarter-over-quarter.
  • 1 fund opened new Aevi Genomic Medicine Inc positions in Q1 2019 and 11 closed out, a net change of -10 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q1 2019 was Renaissance Technologies, an estimated $228K added.
  • The largest Aevi Genomic Medicine Inc seller in Q1 2019 was Adage Capital Partners, an estimated $3.85M sold.

Based on aggregated 13F filings for Q1 2019.